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Natriuretic Peptides,
Ejection Fraction, and Prognosis
Parsing the Phenotypes of Heart Failure*
James L. Januzzi, JR, MD
oston, Massachusetts
Since the first pivotal studies introduced the natriuretic
peptides as biomarkers for the diagnosis of heart failure
(HF), use of both B-type natriuretic peptide (BNP) and its
N-terminal equivalent (NT-proBNP) has grown not only
for this indication, but also for establishing HF prognosis as
well. Indeed, a vast array of studies has established the
natriuretic peptides as the biomarker gold standard to
prognosticate risk for a wide array of relevant complications
in HF (ranging from ventricular arrhythmias to pump
failure) (1,2). In these studies, the prognostic information
provided by BNP and NT-proBNP in HF was independent
of a number of relevant covariates, including left ventricular
ejection fraction (LVEF).
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Despite the utility BNP or NT-proBNP concentrations
for risk prediction in HF, it is necessary to recognize the
potential pitfalls in the interpretation of these versatile
biomarkers. Whereas the severity of HF itself is a prime
factor responsible for the elevation of both, BNP and
NT-proBNP are nonetheless subject to a large number of
factors that may independently influence their values either
upward or downward. These factors (that clinicians should
always keep in mind) include noncardiac aspects (age, body
mass index, renal function, and hemoglobin levels, to name
a few), as well as cardiac structure and function. Among the
most relevant cardiac variables, determining natriuretic
peptide concentrations is LVEF (3). Because LV systolic
dysfunction is typically associated with larger ventricular
chamber radius and greater wall stress—a prime determi-
nant of natriuretic peptide synthesis and release—patients
so affected typically have higher natriuretic peptide values
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consulting income from Sphingotec.than those with normal LV function. In this regard, it has
been known for quite a while that patients with heart failure
and preserved ejection fraction (HFpEF) typically have
lower natriuretic peptide values than do those with heart
failure and reduced ejection fraction (HFrEF) (4). A co-
nundrum is thus present: whereas both BNP and NT-
proBNP tend to be lower in HFpEF, when these peptides
are elevated in this setting, they remain prognostic; this
intriguing circumstance has been relatively poorly studied.
It is in this setting that van Veldhuisen et al. (5) examined
the impact of LVEF on the prognostic merits of BNP in the
COACH (Coordinating Study Evaluating Outcomes of
Advising and Counseling in Heart Failure) study in the
present issue of the Journal. The investigators found—as
expected—that BNP levels were lower in HFpEF, but for a
given BNP concentration, prognosis of those with HFpEF
in COACH was just as poor as those with HFrEF at
matched BNP values. Stated differently, a high BNP in a
patient with HFpEF imparted similar prognostic informa-
tion as it would in someone with HFrEF. Actually, whereas
LVEF was not obviously prognostically impactful, when
considered across the range of ventricular function, an
elevated BNP concentration in the most normal range of
LVEF seemed to be associated with a higher risk than at the
lower ranges of pump function. Although it is previously
established that BNP or NT-proBNP are prognostic inde-
pendently of LVEF (1,2,6), the well-executed analysis
by van Veldhuisen et al. (5) allows for a more in-depth
examination of this phenomenon and raises some impor-
tant questions.
On the one hand, how do we interpret a low natriuretic
peptide concentration in a patient with symptomatic
HFpEF? Do they have a forme fruste of HF? Are they a
different type of HF? Should they be treated differently?
Could some such patients not have the syndrome that we
call HF at all (as argued by the investigators)? Clearly,
clinical experience would dictate that many patients with
HFpEF and a low BNP do in fact have HF, but aggregate
experience suggests such patients often have a lower risk for
complications.
On the other hand, how do we reconcile the fact that
those with HFpEF and a high natriuretic peptide are at least
at comparable risk to those with HFrEF? Should we
evaluate and manage such patients the same way as we do a
patient with HFrEF? Clearly not. van Veldhuisen et al. (5)
show that, compared with those with HFrEF, patients with
HFpEF and markedly elevated concentration of BNP had
more medical comorbidities such as anemia, renal dysfunc-
tion, ischemic heart disease, and atrial arrhythmias. Thus,
BNP testing allows for the identification of a specific HF
phenotype, which may merit considerably different evalua-
tion and management.
Thus, whereas establishment of prognosis is important, it
is reasonable to argue the ultimate goal for measuring
physiologically and prognostically meaningful biomarkers in
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assessment, with the hope for better treatment for the
individual from whom the blood was drawn.
To this point, the investigators rightfully consider how
the results of this and the other studies showing prognostic
merit of BNP or NT-proBNP in HFpEF might be har-
nessed for the betterment of patient care. This is of great
importance, as we sadly do not yet have therapies that
clearly benefit those with the clinical diagnosis of HFpEF.
This may be because HF itself is a syndrome, not a specific
diagnosis, and patients with HFpEF are a mixed bag of
clinical and risk phenotypes, vastly more heterogeneous
than are those with HFrEF. Thus, biomarkers may be of
some use to sort out these phenotypes in HFpEF; in this
regard, early—though somewhat conflicting—data have
recently emerged.
For example, in the PEP-CHF (Perindopril in Elderly
People with Chronic Heart Failure) trial, only those
HFpEF patients with elevated NT-proBNP concentrations
showed potential benefit from allocation to angiotensin-
converting enzyme inhibition (6). On the other hand,
Anand et al. (7) reported that among those treated in the
I-PRESERVE (Irbesartan in Heart Failure With Preserved
Ejection Fraction) study, only those with lower BNP values
demonstrated benefit from angiotensin receptor blockade.
In both trials, however, natriuretic peptides strongly pre-
dicted risk.
It is hard to reconcile these divergent findings, and the
results from I-PRESERVE should make us take pause. Are
some patients with HFpEF and markedly elevated natri-
uretic peptide values so medically complex or prognostically
Figure 1 Phenotypic Definition of the Patient With Heart Failur
GDF  growth differentiation factor; MR-proADM  mid-regional pro-adrenomedullichallenged that they have an immutable risk? Very clearly,more data are needed before the various “faces” of HF are
defined, and the approach will be much more complex than
using a single biomarker such as BNP to clarify care. To this
extent, it is most likely the way to individually phenotype
patients with HFpEF will involve a spectrum of tools,
including clinical variables, blood testing, imaging, and
hemodynamic factors, all integrated to inform specific
aspects about the individual, and lead to better care (Fig. 1).
Biomarkers are only a part of this parsing out of who our
patients are.
Whereas natriuretic peptide “guided” HF care has prom-
ise in the management of patients with chronic HFrEF (8),
we have many miles to go before biomarkers may be used to
trigger better care in HFpEF. Given the broad-based
futility of therapeutic trials for this heterogeneous syn-
drome, directing therapies toward specific HFpEF pheno-
types is worth considering, with the hope to better inform
treatment strategies for these patients. Recent studies have
explored this concept (9); more trials should follow.
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